Y-mAbs Therapeutics, Inc.
YMAB
$8.54
$0.0050.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 37.64% | 23.48% | 2.97% | 24.34% | -39.52% |
| Total Depreciation and Amortization | -25.35% | -30.39% | -15.70% | -20.92% | -3.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.96% | -58.14% | 100.40% | -17.87% | -15.38% |
| Change in Net Operating Assets | 189.83% | -252.53% | 82.01% | -218.87% | 525.50% |
| Cash from Operations | 123.89% | -269.57% | 82.47% | -3,678.86% | 108.57% |
| Capital Expenditure | 100.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 191.23% | -88.44% | 0.72% | -44.31% | 198.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 191.23% | -88.44% | 0.72% | -44.31% | 198.98% |
| Foreign Exchange rate Adjustments | -- | -- | -300.00% | 100.00% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.64% | -679.73% | 90.83% | -570.78% | 171.23% |